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Abstract In the heart, the secretory granules containing the
atrial natriuretic peptides (ANP) and B-type myocardial
natriuretic peptide (BNP) provide the basis for the endocrine
function of this organ. We sought to determine whether atrial
and myocardial secretory granules contain chromogranin/
secretogranin proteins including chromogranin A (CHGA/
Chga), chromogranin B (CHGB/Chgb) and secretogranin II
(SCG2/Scg2). Deconvolution microscopy on immunolabeled
proteins revealed the presence of Chga, Chgb, and Scg2 in
murine cardiac secretory granules. The presence of low
plasma catestatin (CST: mChga364–384) in older mice indi-
cates diminished processing of Chga to CST with advance-
ment of age, which is comparable to that found in humans.
We have previously shown that CST (hCHGA352–372)e x e r t s
potent cardio-suppressive effects on frog and rat heart, but
the source of CST for such action has remained elusive. In
the present study, we found CST-related peptides in
cardiomyocytes and in heart, which establishes an auto-
crine/paracrine function of CST in cardiac tissue. We
conclude that cardiac secretory granules contain Chga, Chgb
and Scg2 and that Chga is processed to CST in murine heart.
Keywords Chromogranin.Secretogranin.Catestatin.
Heart.Cardiomyopathy.Mouse (129svJxC57BL/6)
Introduction
Despiteadvancesintreatment,cardiovasculardiseaseisstillthe
leading cause of morbidity and mortality in the Western world.
A prolonged cardiac hypertrophic state leads to heart failure
and is commonly accompanied by complex changes in protein/
peptide levels in plasma and/or in the heart. Chromogranin A
(human: CHGA; rodent: Chga), a 48- to 52-kDa acidic
secretory protein in homeothermic vertebrates (Helle 2004;
Montero-Hadjadje et al. 2008; Taupenot et al. 2003; Winkler
and Fischer-Colbrie 1992), is a proprotein giving rise to
several peptides of biological importance such as the
dysglycemic hormone pancreastatin (PST) (Gayen et al.
2009; Sanchez-Margalet et al. 2010; Tatemoto et al. 1986),
vasodilator and cardiosuppressive vasostatin (VST) (Aardal et
al. 1993;T o t ae ta l .2008), antiadrenergic, antihypertensive
and cardioinhibitory peptide catestatin (CST) (Angelone et al.
2008; Mahapatra et al. 2005; Mahata et al. 1997, 2000, 2010)
and WE14 which acts as an autoantigen in type 1 diabetes
(Stadinski et al. 2010). Although initially described in the
chromaffin granules of the adrenal medulla, subsequent
studies demonstrate widespread distribution of CHGA/Chga
in endocrine tissues (Fischer-Colbrie et al. 1985;O ’Connor
1983) and in the nervous system (Mahata et al. 1991;
Somogyi et al. 1984). Using immunoelectron microscopy,
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and chromogranin B (Chgb) in the secretory granules in atrial
myoendocrine cells of rat heart and their co-localization with
atrial natriuretic peptide (ANP) (Steiner et al. 1990).
Subsequently, in rat, Chga has been detected in Purkinje
conduction fibers, in both atrium and ventricle, as well as in
H9c2 cardiomyocytes (Weiergraber et al. 2000). A recent
confocal microscopical study clearly shows co-localization of
CHGA with B-type natriuretic peptide (BNP) in human
ventricular myocytes of dilated and hypertrophic hearts
(Pieroni et al. 2007).
The plasma concentration of CHGA is elevated in
established human essential hypertension (O’Connor et al.
2008; Takiyyuddin et al. 1995) and in rodent model of
genetic hypertension (O’Connor et al. 1999). Serum CHGA
levels show distinct correlation with severity of cardiac
dysfunction and act as a predictive factor for mortality in
patients with chronic heart failure (Ceconi et al. 2002).
Recent studies demonstrate a close and independent
association between serum CHGA levels and outcome in
patients with acute coronary syndromes (Estensen et al.
2006; Jansson et al. 2009; Omland et al. 2003) and in
patients with acute (Dieplinger et al. 2009) and chronic
(Ceconi et al. 2002) heart failure. ELISA assays with four
different monoclonal antibodies show a significant amount
of CHGA only in pathologic myocardium (>0.05 μg/g of
tissue) (Pieroni et al. 2007).
The circulating levels of CST decrease in patients with
essential hypertension (O’Connor et al. 2002) and targeted
ablation of the Chga gene in mice increases blood
pressure, which can be “rescued” by replacement with
CST (Mahapatra et al. 2005), indicating a direct role of
CST in preventing hypertension. We have shown that in
addition to its hypotensive action in rodents (Kennedy et
al. 1998; Mahapatra et al. 2005) and in humans (Fung et
al.), CST exerts cardiosuppressive effects on the isolated
Langendorff-perfused rat heart under both basal and
chemically stimulated conditions (Angelone et al. 2008).
T h u s ,i na d d i t i o nt oi t si m p o r t a n tr o l ei nt h ec o n t r o lo f
blood pressure, CST is emerging as a peptide that has
direct cardiovascular actions, suggesting that the negative
inotropism and lusitropism of CST may be important
components of its hypotensive action. In addition, we
have recently found that plasma CHGA is elevated, and its
processing to CST is diminished, in hypertension
(O’Connor et al. 2008). Therefore, in the present study,
we sought to determine the presence of chromogranin/
secretogranin proteins in murine heart and the processing
of Chga to CST by using biochemical and mass spec-
trometry techniques. Our data reveal the presence of Chga,
Chgb and Scg2 and several Chga-derived peptides con-
taining CST motif in murine heart. In addition, processing
of Chga to CST is diminished with advancing age.
Materials and methods
Tissue extraction Very young (10 days, 1-month old), young
adult (2-month, 3-month-old) and adult (6-month-old) mice
with mixed genetic background (129svJxC57BL/6) were
used in this study. Mice were kept in a 12-h dark/light cycle
and were fed standard chow diet. Animal care and sacrifice
were carried out according to the guidelines of Institutional
Animal Care and utilization Committee. Heart and adrenal
glands were collected from isoflurance-anesthetized mice
and were freshly frozen in liquid nitrogen. Tissues were
homogenized using a tissuemizer in TRIS-maleate buffer
(10 mM TRIS-maleate, pH 7.0, sucrose 0.2 M, EDTA
2 mM, Protease inhibitors cocktail and phosphatase inhib-
itors cocktail; Sigma, St. Louis, MO, USA), centrifuged at
8,000g for 30 min and the supernatants were collected.
Cardiomyocyte culture and protein extraction Pups (3–
4 days old) were sacrificed; heart tissues were collected in
ADS buffer (HEPES sodium salt 20 mM, NaCl 116 mM,
D-glucose 5.5 mM, KCl 5.4 mM, Na2HPO4 9m M ,M g S O 4
0.4 mM) and digested with collagenase type II (0.1 mg/100 ml
of ADS buffer; Worthington Biochemical). Cells were pre-
plated for 1 h in uncoated plates to allow the fibroblasts to
attach. The non-adhered cells were then plated in gelatin-
coated plates and cultured in DMEM-low glucose with 10%
FBS and pen/strep for 48 h. After that, medium was replaced
by DMEM with 1% FBS and the cells were cultured for
additional 24 h. Spontaneously beating confluent monolayers
were established 24–48 h after plating. At 72 h, cells were
washed with PBS twice, scrapped in lysis buffer (20 mM
TRIS-Cl, pH 7.4, EDTA 1 mM, NaCl 75 mM, Triton X-100
0.5%, BME 0.1% v/v). Cells were then centrifuged at 14,000g
for 10 min and the supernatants were collected.
Protein estimation Protein concentration was determined
using Bio-Rad protein assay reagent (Bio-Rad laboratories,
Hercules, CA, USA).
SDS-PAGE and immunoblot Proteins were separated using
a 10% SDS-PAGE or a 10–20% Tricine gel (Novex precast
gel; Invitrogen, San Diego, CA, USA) and processed for
western blot analysis as described before (Biswas et al.
2008, 2009). We used rabbit polyclonal anti-human CST
(1:3,000), goat polyclonal anti human CHGB (1:500,
SC-1489; Santa Cruz Biotechnology, Santa Cruz, CA,
USA), rabbit polyclonal ani-human SCG2 (1:1,000), and
goat polyclonal anti-actin (1:500, SC-1615; Santa Cruz
Biotechnology) for immunoblot studies.
Immunofluorescence Cardiomyocyte cultures were grown on
coverslips for 72 h, fixed with 2.5% paraformaldehyde and
processed for immunocytochemistry as described before
354 Cell Tissue Res (2010) 342:353–361(Biswas et al. 2009). The primary antibodies used were: rabbit
polyclonal anti-human CHGA (1:1,000 dilution), goat anti-
CHGB (1:100 dilution, SC-1489), rabbit anti-human SCG2
(1:2,000 dilution), goat anti-beta myosin heavy chain (MYH,
1:100, SC-12117) and goat anti-atrial natriuretic peptide
(ANP, 1:100, SC-18811). Pictures were taken on a deltavision
microscope as described before (Courel et al. 2008).
Purification of CST-containing peptides Frozen heart tissue
(6-month-old animals)wasextracted in 1 M acetic acid,boiled
for 5 min, and homogenized. The supernatant (1 mg protein)
was subjected to reverse phase HPLC purification (Symmetry
C18 column, 5 μm, 4.6×250 mm; Waters, Milford, MA,
YSA). Proteins were eluted with a gradient (25–60% over
15–85 min) of acetonotrile at a flow rate of 0.5 ml/min.
Fractions (1 min) were collected, lyophilized and spotted on a
nitrocellulose membrane, and immunostained with a CST-
specific antibody. The CST-positive fractions from different
run were lyophilized, pooled and subjected to mass spec
analysis by electrospray method.
Anti-CST immunoprecipitation Frozen heart tissues
(1-month-old animals) were homogenized in Tris-maleate
buffer and the resulting supernatants were subjected to
immunoprecipitation. Tissue extracts (2 mg and 1 mg) were
pre-cleared by incubating with normal rabbit serum in 1×
immunoprecipitation buffer (IP buffer: 10 mM TRIS-Cl,
pH 7.5, Triton X-100 0.1%, NaCl 140 mM). Immunuopre-
cipitation was carried out overnight at 4°C using polyclonal
anti-human CST antibody. Antigen–antibody complexes
were pulled out using protein G plus/protein A agarose
(Calbiochem, San Diego, CA, USA) and washed 2 times
with 1X IP buffer. The bound proteins were eluted from the
beads either in Tricine loading dye for immunoblot analysis
or with acetonitrile/water/TFA for mass spec analysis.
Mass spec analysis Electrospray and MALDI TOF analysis
were carried out on a QTOF (QSTAR Elite) and Voyager
DeSTR mass spectrometer respectively at the biomolecular
and proteomics mass spectrometry facility, UCSD, depart-
ment of Chemistry and Biochemistry as described before.
The resulting peptide masses were analyzed in the program
protein prospector (http://prospector.ucsf.edu) to identify
the possible fragments and were listed.
CST EIA CST EIA was carried out using a CST specific
EIA kit (EK-053-29) from Phoenix Pharmaceutical
(Burlingame, CA, USA)
Statistical analysis Biochemical data are expressed as the
mean±SEM. Multiple comparisons were made using one-
way ANOVA followed by Bonferroni’s post hoc test.
Statistical significance was concluded at p<0.05.
Results
Expression of chromogranin/secretogranin proteins
in murine heart and processing of Chga to CST in heart
as compared to adrenal gland
To determine the expression of chromogranin/secretogranin
proteins, primary culture of cardiomyocytes from 3- to 4-
day-old pups were analyzed by immunocytochemistry.
Deconvolution microscopy shows punctuate staining of
chromogranin/secretogranin proteins, which indicates dis-
crete vesicular distribution of Chga (Fig. 1a), Chgb
(Fig. 1b) and Scg2 (Fig. 1c) proteins in the cytoplasm of
murine cardiomyocytes. As a positive control, we detected
vesicular staining for the myocyte specific protein
(MYH: ∼60% of cells) (Fig. 1d) and atrial natriuretic
peptide (ANP: ∼4% of cells) (Fig. 1e). Cardiomyocyte cell
extracts showed several distinct low molecular mass
(ranging from 25 to 37 kDa) CST-positive fragments, along
with low abundance full-length Chga (ran at ∼75 kDa)
(Fig. 1f).
To identify CST-containing fragments, we carried out
SDS-PAGE followed by CST immunoblot in heart and
adrenal extracts. Adult heart extracts revealed three CST-
positive fragments with masses of ∼37, ∼31 and ∼15 kDa
(Fig. 1g). Murine heart also showed faint immunoreactivity
at ∼75 kDa, which is the apparent migratory behavior of
full-length Chga in SDS-PAGE gel. In addition, we
detected a very high molecular mass form of Chga, possibly
representing the proteoglycan form. Because of the pres-
ence of a high number of acidic amino acid residues within
the primary structure of chromogranin/secretogranin pro-
teins, these proteins run anomalously on SDS-PAGE and
their apparent molecular weight differs from the weight
deduced by primary amino acid sequence. In contrast to
Chga, Chgb showed a major full-length form and also some
low molecular mass fragments (Fig. 1g). Scg2, on the other
hand, showed extensive aggregation or modification as
evidenced by the presence of high molecular mass protein
as major signal along with some low molecular mass
fragments. Compared to the heart extract, the full-length
Chga appeared to be highly prevalent in the adrenal extract;
the major CST positive fragment ran at 75 kDa. After
exposing the lower part of the membrane for a longer
period of time, we detected comparable processing products
of Chga between adrenal gland and heart as evidenced by
the presence of smaller, processed forms of Chga with
masses of ∼37, ∼27, and ∼15 kDa in the adrenal extract
(Fig. 1 g). Although both the adrenal gland and heart
express the processed forms, the ratio of processed to full-
length form is much higher in the heart compared to the
adrenal gland indicating an extensive processing of Chga in
the heart as compared to the adrenal gland.
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murine heart. The localization of Chga (a), Chgb (b) and Scg2 (c)
were assessed in primary culture of cardiomyocytes, derived from
3- to 4-day-old pups. Cardiomyocytes were stained with primary
antibodies specific for each chromogranin/secretogranin proteins and
the cardiomyocyte specific markers such as myosin heavy chain
(MYH) (d) and atrial natriuretic peptide (ANP) (e). The secondary
antibodies used were donkey anti-rabbit IgG-Alex Flur 488 (green
fluorescence, 1:250) and donkey anti-goat IgG-Alex Flur 594 (red
fluorescence, 1:350). Nuclei were visualized with Hoechst 33342
(blue). Cells were examined by deconvolution microscopy using
a ×60 objective (scale bar 5 μm) for the upper panel and a ×20
objective (scale bar 10 μm) for the lower panel. f Cardiomyocyte cell
extracts (lane 1 20 μg protein and lane 2 40 μg protein) were analyzed
by SDS-PAGE followed by immunoblot with a CST specific antibody.
g Freshly frozen adult (6-month-old) mice heart and adrenal tissues
were homogenized in TRIS-maleate buffer and were subjected to
SDS-PAGE and immunoblot analysis. Heart extracted proteins
(∼75 μg) were run by SDS-PAGE for the detection of Chga (by
rabbit anti-human CST), Chgb (by goat anti-human CHGB) and Scg2
(by rabbit anti-human SCG2). Adrenal extracts (proteins in lane 1
2 μg, lane 2 15 μg, lane 3 30 μg, and lane 4 60 μg) were also run by
SDS-PAGE for the detection of Chga (by rabbit anti-human CST). For
adrenal extract the full-length Chga signal was shown in the upper
panel and the low molecular mass fragments were shown in the lower
panel
356 Cell Tissue Res (2010) 342:353–361Age-dependent processing of Chga in murine heart
Although Chga is overexpressed in humans with essen-
tial hypertension and in genetic model of rodent
hypertension, CST showed diminished expression in
hypertensive subjects and in normotensive individuals
with a family history positive for hypertension. Since
hypertension is a late penetrating disease, and CST plays
crucial roles in the development of hypertension, we
sought to determine whether processing of Chga to CST
in murine heart is altered with age. The full-length Chga
signal (ran ∼75 kDa) as well as the intensity of the ∼37 kDa
Chga C-terminal fragment were increased in older animals
(Fig. 2a). However, the intensity of a low molecular mass
CST-specific peptide (less than ∼15 kDa) decreased in the
heart of older animals (Fig. 2a). Consistent with immunoblot
findings, CST EIA displayed a significant reduction of
endogenous CST peptide in the heart extract of older mice
(30–90 days old) as compared to younger (10-day-old) mice
(Fig. 2b).
Identification of CST-containing peptides in adult mouse
heart
Mouse heart extract was purified using the RP-HPLC
column (Fig. 3) and the fractions collected for slot blot
analysis. From the anti-CST slot blot, two fractions eluting
at 48% (61–63 min) and 54% (73–76 min) acetonitrile were
positive for CST immunoreactivity (Fig. 3b). To evaluate
the apparent molecular mass of Chga C-terminal CST-
containing fragments in these fractions, each fraction was
lyophilized, pooled and subjected to mass spec analysis.
Electrospray mass spec analysis revealed the presence of
several CST-spanning peptides in heart extracts (Table 1).
Among them, the peptides of mass 5,051.60 and 5,641.11,
representing Chga356–398 and Chga357–404 or Chga358–405,
respectively, had considerable overlap with the N-terminal
part of the long CST sequence, mChga356–384. The peptides
of mass 4,757.50, 5,244.85 and 2,478.34 contained a
significant part of the N-terminal of short CST sequence,
mChga364–384 (Table 1).
Immunoprecipitation of CST related peptides from young
mouse heart
Since young animals showed more low molecular mass
CST fragments (<15 kDa; see Fig. 2a), we sought to
purify CST related peptides from 1-month-old mice with
an alternate strategy of immunoprecipitation. SDS-PAGE
analysis (on a 10–20% Tricine gel) of immunoprecipi-
tated complex showed several fragments ranging from 20
to 150 kDa (Fig. 4a, left panel). Besides these high
molecular mass fragments, the longer exposure of the
lower part of the membrane revealed the presence of a
peptide that ran at ∼7k D a( F i g .4a, middle panel). As
a positive control, we ran synthetic human CST
(hCHGA352–372;M o l e c u l a rm a s s ∼2.4 kDa) (Fig. 4a,
right panel). Although we did not achieve a good
separation between 2 and 7 kDa protein even on a 10–
20% gel, our results indicate the presence of a low
molecular mass (in the range of 2–7k D a )f r a g m e n ti nt h e
anti-CST immunoprecipitated complex. The MALDI-
TOF analysis showed a major peptide of ∼11 kDa
corresponding to the C-terminal Chga derived fragment
Chga283–384 (Fig. 4b and Table 2). Several peptides with
CST motif have been identified. Among them, peptides
of mass 4,097 and 6,224 overlapped with the N-terminal
sequence of short CST, mChga364–384 (Table 2).
Fig. 2 Age-dependent processing of Chga to CST in murine heart.
Heart from different age groups of mice (age in days: 10, 30, 60 and
90) were collected, homogenized and subjected to SDS-PAGE and
immunoblot using a CST-specific antibody (rabbit anti-human CST)
(a). b The endogenous CST concentrations were measured from tissue
extracts using a CST EIA kit. CST concentrations are expressed in
pg/μg of protein
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Consistent with previous findings (Pieroni et al. 2007;
Steiner et al. 1990; Weiergraber et al. 2000), we detected
Chga and Chgb proteins in cardiomyocytes by deconvolu-
tion microscopy. Punctate staining patterns indicate vesic-
ular storage of chromogranin/secretogranin proteins in
cardiomyocytes in congruence with the elegant demonstra-
tion by Winkler’s group using immunoelectron microscopy
(Steiner et al. 1990). In addition to Chga and Chgb, we also
found Scg2 in cardiomyocytes, which has not been shown
before. A recent confocal microscopical study reveals co-
localization of CHGA with BNP in human ventricular
myocytes of dilated and hypertrophic hearts (Pieroni et al.
2007). CHGA has also been detected in Purkinje conduc-
tion fibers, in both atrium and ventricle, as well as in H9c2
cardiomyocytes (Weiergraber et al. 2000).
Tota’s group was the first to demonstrate the cardiosup-
pressive effects of the N-terminal CHGA peptide VST on
isolated and perfused heart preparations of eel, frog and rat,
and to establish VST’s direct involvement in the regulation
of the contractile performance of hearts beating under basal
Fig. 3 Identification of CST-
related peptides from heart
extract. Mice hearts (6 months
old) were homogenized in acetic
acid and subjected to reverse
phase HPLC purification.
The proteins were eluted (the
chromatogram showing protein
elution as measured at 214 nm
with time is shown in (a)), with
a gradient of acetonitrile and
the fractions were collected,
lyophilized and spotted onto
nitrocellulose membrane to
probe with a CST-specific
antibody (b). Fraction numbers
are shown on the right of the
respective slot blot (b)
Mass (monoisotopic)
submitted
Mass (monoisotopic)
matched
Sequence Cleavage sites
4,989.67 4,989.37 325–364 E/E R/S
4,989.54 349–390 K/E P/S
5,148.74 5,148.52 328–369 E/E S/F
5,057.51 5,057.52 339–380 K/R P/G
3,061.55 3,061.50 342–367 S/R K/L
4,341.31 4,341.17 344–380 M/D P/G
3,034.66 3,034.56 346–371 Q/L R/T
4,989.78 4,989.54 349–390 K/E P/S
5,051.6 5,051.47 356–398 R/L E/A
5,641.11 5,643.69 357–404/358–405 L/E or E/G E/E or E/G
3,294.72 3,294.67 360–387 E/D G/W
4,757.5 4,751.41 364–403 D/R F/E
5,244.85 5,244.63 365–408 R/S E/E
2,478.34 2,478.36 367–387 M/K G/W
1,754.94 1,754.87 369–383 L/S Q/L
2,676.45 2,676.41 369–390/370–391 S/F or L/S S/S or P/S
5,187.64 5,187.51 369–412 L/S S/A
2,369.22 2,369.2 376–395 Y/G D/S
3,828.98 3,828.88 378–409 F/R E/E
2,008.99 2,009.00 379–395 R/D D/S
Table 1 Catestatin-related
peptides detected by mass
spectrometry from reverse phase
HPLC purification of heart
extract. The CST-immuno
positive fractions from reverse
phase HPLC, as detected by slot
blot, were lyophilized, and
subjected to electrospray mass
spectrometry. The resulting
peptides generated in the
catestatin region are listed
in bold
Mouse catestatin sequence:
[K
354R
355]
LEGEDDPDR
364SMKLSFR
TRAYGFRDPGPQL[R
385R
386]
Long CST: mChga356–384
Short CST: mChga364–384
358 Cell Tissue Res (2010) 342:353–361(i.e., non-stimulated) as well as stimulated (e.g., isoproter-
enol) conditions (Cerra et al. 2004, 2006; Imbrogno et al.
2004; Tota et al. 2003). In subsequent studies, they have
detected natural VST-containing peptides in rat heart
(Glattard et al. 2006), which basically established an
autocrine/paracrine regulation of cardiac function by VST.
We have recently demonstrated that, like VST, CST also
induces cardio-suppressive effects in frog and rat heart
(Angelone et al. 2008; Mazza et al. 2008). Therefore, it was
crucial to demonstrate that CST-containing peptides are in
fact generated in the heart. The present studies clearly show
that CST-containing peptides are indeed generated in
murine heart, which establishes an autocrine/paracrine
action of CST in cardiac function. Immunoprecipitation of
heart extracts with CST followed by immunoblots confirms
generation of CST peptide in heart. In fact, we have
previously shown that CST inhibits catecholamine secretion
through an autocrine/paracrine mechanism (Mahata et al.
1997). It is interesting to note that heart extracts or
cardiomyocytes contain very little amount full-length Chga
as opposed to adrenal gland where the major band
represents the full-length Chga, which is consistent with
the findings that catecholamines inhibit proteolytic process-
ing of Chga in the adrenal medulla (Wolkersdorfer et al.
1996). The high molecular weight bands detected for Chga
and Scg2 possibly represent the proteoglycan form of these
proteins. Of note, the proteoglycan form for Chgb is
undetectable in murine heart.
It appears that processing of Chga to CST is diminished
in heart with advancing age as judged by low CST. This is
particularly relevant in context of hypertension, which is a
late-penetrating disease where CST plays a crucial role. We
have previously shown that CST (low) is inversely
proportional to CHGA (high) in hypertensive human
subjects, for which we have implicated a diminished
processing of CHGA to CST (O’Connor et al. 2008). In
this context, it should be mentioned that CHGA has been
shown to increase in proportion to severity of cardiac
dysfunction and to be associated with prognosis in patients
with both chronic and post-infarction heart failure (Ceconi
et al. 2002; Omland et al. 2003). In addition, it has been
shown recently that plasma CHGA levels obtained within
the first 24 h of admission are independently associated
with the incidence of death in patients with acute coronary
syndromes (Jansson et al. 2009).
In conclusion, we have detected chromogranin/secreto-
granin proteins including Chga, Chgb and Scg2 in murine
heart where Chga is processed to CST-related peptides,
implicating an autocrine/paracrine regulation of cardiac
function by CST.
Fig. 4 Anti-CST immunoprecipitation from the heart extract. Mice
heart (1-month-old animal) were homogenized in TRIS-maleate buffer
and subjected to immunoprecipitation from 2 to 1 mg protein with
anti-CSTantibody. The antigen-antibody complexes were pulled down
with Protein A/G beads and subjected to immunoblot analysis (lane 1
IP from 2 mg protein, lane 2 IP from 1 mg protein) (a). In (a), rabbit
anti-human CST antibody was used to detect CST-related peptides.
The middle panel of (a) showed the darker exposure of the lower part
of the gel. The right panel of (a) showed the running position of the
synthetic human CST in the same gel. For MALDI-TOF (b), proteins
eluted from the beads with acetonitrile/water/TFA were lyophilized
and analyzed by mass spec
Mass (average) submitted Mass (average) matched Sequence
4,097 4,097.65 339–372/340–373
4,098.62 365–399
4,228 4,225.82 338–372
5,733 5,736.46 331–377
5,738.53 342–389
5,961 5,961.67 333–381
6,224 6,218.86 365–417
11,920 11,920.02 283–384
Table 2 Catestatin spanning
peptides detected by mass
spectrometry from immunopre-
cipitation of heart extract.
Heart extract was subjected to
immunoprecipitation with a
CST-specific antibody. Proteins
were eluted from the beads
with acetonitrile/water/TFA,
lyophilized and analyzed by
MALDI-TOF. The detected
peptides are summarized
below
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